Additionally, empagliflozin improves cardiac mitochondrial function, reduces cardiac fibrosis and increases the survival rate in mice with heart and skeletal muscle-specific manganese superoxide dismutase (MnSOD)-deficiency (MnSOD-cKO mice under the control of the muscle creatine kinase promoter)[212], which is a mitochondrial antioxidant enzyme. The gene discussed is SOD2; the disease is fibrosis.